A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
Clinical trial NCT02927340 · UNKNOWN
Trial details
- NCT number
- NCT02927340
- Sponsor
- Massachusetts General Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-01
- Primary completion
- 2022-01-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.